Overview

The Mesothelioma (Amendment) Bill amends the Mesothelioma Act 2014 to add a research supplement to the existing levy on insurers. This supplement will fund research into mesothelioma, a cancer linked to asbestos exposure.

Description

This bill modifies the 2014 Mesothelioma Act by introducing a "research supplement" to the levy imposed on insurers. This supplement, capped at 1% of the existing levy, will be used to fund mesothelioma research. The Secretary of State must consult insurers, medical charities, research foundations, and other relevant stakeholders before setting the exact percentage and allocation of funds. The scheme administrator will manage the supplement, potentially delegating administration to an appropriate research funding body. Funds can be held and invested before allocation. The bill applies to England, Wales, Scotland, and Northern Ireland and comes into effect upon passage.

Government Spending

The bill will not directly increase or decrease government spending. Instead, it mandates a small percentage increase in the levy on insurers, with the resulting funds dedicated to mesothelioma research. The exact financial impact depends on the final percentage of the research supplement set by the Secretary of State, but it is capped at a maximum of 1% of the existing levy.

Groups Affected

• Insurers: Will face a slightly increased levy to fund the research supplement.
• Mesothelioma sufferers and their families: Could indirectly benefit from advancements in mesothelioma research funded by the supplement.
• Medical charities and research foundations: May receive funding for mesothelioma research.
• Researchers: May receive grants to conduct mesothelioma research.

Powered by nyModel